Plasmodium falciparum infecting hemoglobin (Hb)H and/or Hb Constant Spring erythrocytes has higher resistance to artemisinin in vitro than when infecting normal erythrocytes. This is due to low drug accumulation of infected erythrocytes resulting from competition with uninfected variant erythrocytes, which have a higher accumulation capacity than genetically normal cells. Drug accumulation of the parasite was shown to be saturable and dependent on metabolic energy. The 50% inhibitory concentrations (IC5,'s) for the parasite in HbH/Hb Constant Spring erythrocytes were decreased when normal erythrocytes were added to the infected cells, and correspondingly, the IC5R's in normal erythrocytes were increased when HbH/Hb Constant Spring erythrocytes were added to the infected cells.
Introduction
Resistance of the malaria parasite Plasmodium falciparum to chloroquine and other drugs in various parts of the world necessitates the development of new effective antimalarials (1) . Derivatives of artemisinin (qinghaosu) (2, 3) comprise a new family of such drugs presently undergoing development and clinical trials. Their fast action and effectiveness against chloroquine-resistant strains of the parasites make them potentially Southeast Asia and the Pacific. These areas also have a high incidence ofthalassemia and abnormal hemoglobins (4), some genotypes for which are associated with innate resistance to falciparum malaria (5, 6) . Hence, hemoglobin (Hb)'H-containing erythrocytes from a-thalassemic (genotype a-thalassemia 1 /a-thalassemia 2, --/ -a) or a-thalassemic/Hb Constant Spring individuals (genotype a-thalassemia 1 /Hb Constant Spring, --/acsa) have been shown to be resistant to infection by P.falciparum in vitro (7, 8) . Enhanced immune recognition and clearance of parasitized erythrocytes have also been implicated as contributing to the apparent protective effect ofthalassemia against falciparum malaria (9) . These experimental results support an earlier observation that prevalence ofthe genes for a-thalassemia parallels the endemicity of falciparum malaria in the Pacific Islands (5). The high frequencies of genes for various types of thalassemia and abnormal hemoglobins in Southeast Asia and various other parts of the world make it relevant to ask whether antimalarial drugs would have the same efficacy in malaria patients carrying these genes as in genetically normal patients. This question also carries implications for development of drug resistance, which originated in Southeast Asia for a number ofantimalarials, including chloroquine ( 1) . If the drug concentrations that are sufficient to kill the parasites in normal patients were suboptimal for genetically variant patients, these would impose selective pressure on the parasites to become drug resistant.
We have reported earlier that P. falciparum infecting HbH and/or Hb Constant Spring erythrocytes displays more resistance to artesunate, a derivative of artemisinin, and chloroquine than the same parasite strain infecting genetically normal erythrocytes ( 10) . This novel host effect on sensitivity to artesunate is especially striking in view of the facts that these genetically variant erythrocytes are already subject to high oxidative stress ( 11) , that P. falciparum is sensitive to oxidative stress (12) (13) (14) , and that artemisinin probably exerts its action through an oxidative mode ( 15-17). Two possible explanations ofthe observation were raised: the higher levels ofantioxidative enzymes in the variant erythrocytes could give rise to a compensation effect lessening the oxidative damage potential of artemisinin, and/or the infected variant erythrocytes could not accumulate as much drug as infected normal erythrocytes. In this paper, we show that the latter explanation is correct. Furthermore, we show that the reduction in artemisinin accumulation of infected variant erythrocytes is due partly to competition with uninfected erythrocytes for the drug, and partly to lower drug accumulation capacities of the parasite.
Methods
Culture ofP. falciparum. Chloroquine-resistant K, strain was obtained from Kanchanaburi Province, Thailand, and maintained in vitro by the candle jar technique of Trager and Jensen ( 18) . The cultures were synchronized at ring stage by 5% sorbitol treatment ( 19) with 400 ,Al of 15% hydrogen peroxide at 60'C overnight. 4 ml ofliquid scintillation fluid was added and the radioactivity was determined.
In the study of effect of iodoacetamide on drug uptake, the cells were preincubated at 370C with 500 ,Ad of 100 MM iodoacetamide in incomplete medium. After 1 h of incubation, 130 Ml of ['4C]-artemisinin was added to the cell suspension to obtain a final concentration of 100 nM and a 10% cell suspension. The cells were mixed and incubated further for 2 h, and the drug accumulation was determined as above.
Statistical analysis. The Mann-Whitney U test was used for comparing the data from normal and variant erythrocytes based on independent random samples.
Results
As has been observed before, the IC50's for artemisinin against P. falciparum infecting HbH and HbH/Hb Constant Spring erythrocytes are significantly higher than against the parasite in genetically normal erythrocytes (Fig. 1 ) . The basis for the differences in IC50's was earlier ( 10) suggested as being due to differences in oxidative stresses in the infected variant and normal erythrocytes, or due to differences in drug accumulation. The latter possibility was explored through the use of radiolabeled artemisinin. Fig. 2 A shows the accumulation of ["C]-artemisinin at the initial concentration of 130 nM by infected genetically normal erythrocytes (6.6% parasitemia), infected HbH erythrocytes (6.6% parasitemia), and HbH/ Hb Constant Spring erythrocytes (5.3% parasitemia), while Fig. 2 B shows the drug accumulation by control erythrocytes that were not exposed to the parasite. Since the final medium concentration was decreased to different extents by the different amounts of the drug accumulated into the cells, the amounts ofaccumulation were divided by the final medium concentration in order to obtain normalized accumulation, which can be defined as accumulation capacities. (Fig. 2, C and F) . The accumulation capacities of infected erythrocytes decreased rapidly with increasing initial concentration ofthe drug up to -2 MuM for all three genetic types, indicating saturability of the binding sites (Fig. 3) (Fig. 3  A) , was about two and three times that of the parasites infecting HbH (Fig. 3 B) and HbH/Hb Constant Spring erythrocytes (Fig. 3 C) , respectively, at therapeutic concentrations (< 100 nM), indicating differences in availability of specific sites. The (Fig. 
B).
When the data from drug sensitivity and accumulation experiments, which were obtained from the same set of samples, were combined to explore further the basis of differences in drug sensitivities, an inverse relationship was found between the final medium concentration of the drug incubated with uninfected erythrocytes of different genetic types and the IC50 values for parasites infecting these erythrocytes (Fig. 5 A) . This indicates that the increase in observed IC50 values of parasites infecting variant erythrocytes was at least partly due to lowered medium concentration. Fig. 5 B shows that the IC50 values were correlated with the accumulation capacities of uninfected erythrocytes, which can account for the lowered medium concentration and increased IC50 values for infected variant erythrocytes. In agreement with the results in Fig. 2 , the accumulation capacity of the parasite, corrected for lowered medium concentration, was also influenced by the genetic type of the erythrocyte that it has infected. Fig. 5 C shows an inverse correlation between the IC50 values and normalized parasite drug accumulation capacities, indicating that the former is also influenced by the capacities for drug accumulation ofthe parasite inside the variant cells.
To prove further that the differences in IC50 values for parasites infecting various genetic types of erythrocytes were due to different drug accessibilities, and to assess the relative impor could begin a new cycle, should be independent ofthe composition of uninfected cells with regard to their genetic types if these were determined only by the accumulation capacities of the infected cells, but would be dependent on the uninfected cell composition if the accumulation capacities are wholly or partly determined by competition between infected and uninfected cells. Data in Fig. 6 (Fig. 7) . It can therefore be concluded that the IC50 values are to a large extent influenced by drug accumulation of uninfected erythrocytes, thereby lowering the medium concentration. This conclusion is also supported by another set of experiments determining the IC50 values for infected genetically normal and variant erythrocytes at different hematocrit values in the culture. As Fig. 8 shows, the IC50 values for infected HbH and HbH/Hb Constant Spring erythrocytes were decreased with decreasing hematocrit values, whereas the IC50 values for infected genetically normal erythrocytes were independent of the hematocrit. These experiments show that the major factor leading to apparent drug resistance of the parasite infecting the variant erythrocytes is competition in drug accumulation by uninfected variant erythrocytes.
Discussion
The resistance to artemisinin of P. falciparum infecting HbH and HbH/Hb Constant Spring erythrocytes (Fig. 1 ) supports our previous finding on similarly increased resistance to artesunate (10) . In this report, we have shown further that such increased resistance is mainly due to the fact that uninfected HbH and HbH/Hb Constant Spring erythrocytes have high accumulation capacity for artemisinin (Figs. 2, B (Fig. 6) (Fig. 7) . Decrease of the hematocrit value in the culture with variant erythrocytes, thereby leading to less drug accumulation by uninfected erythrocytes, also led to a corresponding decrease in IC50, while the hematocrit value had little influence on IC50 ofparasites infecting genetically normal erythrocytes (Fig. 8) .
Although drug accumulation of uninfected HbH and HbH/Hb Constant Spring erythrocytes was far higher than uninfected genetically normal erythrocytes, the accumulation of all genetic types was linear with external drug concentration to > 2 ,gM. By contrast, the accumulation by the parasites was saturable, consistent with a previous report in which the accumulation of dihydroartemisinin showed saturation at drug concentrations of > 3.86 1uM (22) . Furthermore, temperature dependence and partial inhibition by iodoacetamide of parasite drug accumulation (Fig. 4) indicated at least partial dependence on metabolic energy. Except for dependence on temperature of HbH erythrocytes, there was little effect of temperature or iodoacetamide on drug accumulation ofuninfected erythrocytes. Our results reported here carry implications for the treatment of P. falciparum-infected patients with artemisinin or their derivatives, especially in the areas with high prevalence of thalassemic/hemoglobinopathic genes, which are largely the same as those with malaria endemicity (5) . Hence, ifthe differences in sensitivity also exist at the clinical level, there will be a 0. ( 16) . Therefore, the variation in effective dosage and therapeutic index of artemisinin for treatment of P. falciparum infection in these groups of patients should be investigated.
